Chronic administration of a partial agonist at strychnine-insensitive glycine receptors: a novel experimental approach to the treatment of ischemias.
During the past decade, converging lines of evidence have linked the abnormal release or leak of excitatory amino acids to the neurodegeneration associated with a wide range of pathologies including cerebral ischemias, Huntington's disease, and AIDS dementia (Coyle and Robinson, 1987; Lipton, 1994; Meldrum, 1994). Pharmacological studies indicate that activation of both ionotropic and metabotropic glutamate receptors can substantially contribute to excitotoxic cell damage (Choi, 1992; Pizzi et al., 1993; Sheardown et al., 1993; Xue et al., 1994). Based on these findings, therapeutic strategies based on blunting or blocking glutamatergic transmission may be useful in treating a variety of neurodegenerative disorders.
Fossom
L H
LH
Laboratory of Neuroscience, NIDDK, National Institutes of Health, Bethesda, MD, USA.
Skolnick
P
P
D015526:AIDS Dementia Complex / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D000596:Amino Acids / Q000494:pharmacology* / Q000627:therapeutic use; D000598:Amino Acids, Cyclic; D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D009410:Nerve Degeneration; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018009:Receptors, Glycine / Q000819:agonists* / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D013331:Strychnine / Q000494:pharmacology
D000596:Amino Acids; D000598:Amino Acids, Cyclic; D018696:Neuroprotective Agents; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate; C023863:1-aminocyclopropane-1-carboxylic acid; D013331:Strychnine